Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Company Overview

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas. By leveraging its platform to validate novel targets and generate lead candidates, the company aims to address unmet medical needs where dysregulated lipid environments drive disease progression.

Headquartered in South San Francisco, California, Gyre Therapeutics was founded in 2021 and completed its initial public offering on the Nasdaq Global Market under the ticker symbol GYRE in mid-2023. Operating primarily in the United States, the company collaborates with academic researchers and industry partners to advance its discovery efforts. Through its innovative focus on membrane biochemistry, Gyre seeks to build a diversified portfolio of first-in-class small-molecule therapies.

Key Stats

• Today's Range: $6.41 to $6.89
• 50-Day Range: $5.64 to $7.34
• 52-Week Range: $5.44 to $9.42
• Volume: 56,021 shs
• Average Volume: 53,731 shs
• Market Capitalization: $764.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Reduce

Gyre Therapeutics Stock Analysis - MarketRank™

Gyre Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 771st out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Gyre Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

Gyre Therapeutics has a consensus price target of $16.00, representing about 133.2% upside from its current price of $6.86.

Amount of Analyst Coverage

Gyre Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gyre Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.47) per share.

Price to Book Value per Share Ratio

Gyre Therapeutics has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.73% of the float of Gyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gyre Therapeutics has a short interest ratio ("days to cover") of 31.05, which indicates bearish sentiment.

Change versus previous month

Short interest in Gyre Therapeutics has recently decreased by 4.27%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gyre Therapeutics does not currently pay a dividend.

Dividend Growth

Gyre Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Gyre Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.50% of the stock of Gyre Therapeutics is held by insiders.

Percentage Held by Institutions

23.99% of the stock of Gyre Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/04/2026
• 12th Annual Cantor Fitzgerald Global Healthcare Conference: 9/09/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GYRE
• Previous Symbol: NASDAQ:GYRE
• CIK: 1124105
• Web: www.catalystbiosciences.com
• Phone: (619) 949-3681
• Fax: 336-480-2107
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Gyre Therapeutics: $16.00
• High Price Target: $16.00
• Low Price Target: $16.00
• Potential Upside/Downside: +133.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.03 million
• Net Margins: -15.47%
• Pretax Margin: -10.30%
• Return on Equity: -6.57%
• Return on Assets: -5.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.26
• Quick Ratio: 3.86

Sales & Book Value

• Annual Sales: $116.59 million
• Price / Sales: 6.56
• Cash Flow: $0.24 per share
• Price / Cash Flow: 28.98
• Book Value: $1.28 per share
• Price / Book: 5.36

Miscellaneous

• Outstanding Shares: 111,510,000
• Free Float: 100,917,000
• Market Cap: $764.96 million
• Optionable: No Data
• Beta: 1.92